Last Updated : December 14, 2018
Details
FilesGeneric Name:
Pertuzumab-Trastuzumab Combo Pack
Project Status:
Complete
Therapeutic Area:
Early Breast Cancer
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Perjeta-Herceptin Combo Pack
Project Line:
Reimbursement Review
Project Number:
PC0127-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
420 mg/14 mL
Tumour Type:
Breast
Indications:
Early Breast Cancer
Funding Request:
For 18 cycles for the adjuvant treatment of HER2-positive early breast cancer patients at high risk of recurrence. High risk of recurrence is defined as either node-positive or hormone receptor-negative disease
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : December 14, 2018